PMID- 32055644
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2329-0501 (Print)
IS  - 2329-0501 (Electronic)
IS  - 2329-0501 (Linking)
VI  - 16
DP  - 2020 Mar 13
TI  - Human iPSC-Derived Neural Crest Stem Cells Exhibit Low Immunogenicity.
PG  - 161-171
LID - 10.1016/j.omtm.2019.12.015 [doi]
AB  - Recent clinical trials are evaluating induced pluripotent stem cells (iPSCs) as a 
      cellular therapy in the field of regenerative medicine. The widespread clinical 
      utility of iPSCs is expected to be realized using allogeneic cells that have 
      undergone thorough safety evaluations, including assessment of their 
      immunogenicity. IPSC-derived neural crest stem cells (NCSCs) have significant 
      potential in regenerative medicine; however, their application in cellular 
      therapy has not been widely studied to date, and no reports on their potential 
      immunogenicity have been published so far. In this study, we have assessed the 
      expression of immune-related antigens in iPSC-NCSCs, including human leukocyte 
      antigen (HLA) class I and II and co-stimulatory molecules. To investigate 
      functional immunogenicity, we used iPSC-NCSCs as stimulator cells in a one-way 
      mixed lymphocyte reaction. In these experiments, iPSC-NCSCs did not stimulate 
      detectable proliferation of CD3(+) and CD3(+)CD8(+) T cells or induce cytokine 
      production. We show that this was not a result of any immunosuppressive features 
      of iPSC-NCSCs, but rather more consistent with their non-immunogenic molecular 
      phenotype. These results are encouraging for the potential future use of 
      iPSC-NCSCs as a cellular therapy.
CI  - Crown Copyright (c) 2020.
FAU - Mehler, Vera J
AU  - Mehler VJ
AD  - Endocrinology Section, Biotherapeutics, National Institute for Biological 
      Standards and Control (NIBSC), Blanche Lane, Potters Bar EN6 3QG, UK.
AD  - Division of Infection and Immunity, University College London, Gower Street, 
      London WC1E 6BT, UK.
FAU - Burns, Chris J
AU  - Burns CJ
AD  - Endocrinology Section, Biotherapeutics, National Institute for Biological 
      Standards and Control (NIBSC), Blanche Lane, Potters Bar EN6 3QG, UK.
FAU - Stauss, Hans
AU  - Stauss H
AD  - Division of Infection and Immunity, University College London, Gower Street, 
      London WC1E 6BT, UK.
FAU - Francis, Robert J
AU  - Francis RJ
AD  - Biological Imaging Group, Analytical and Biological Sciences, NIBSC, Blanche 
      Lane, Potters Bar EN6 3QG, UK.
FAU - Moore, Melanie L
AU  - Moore ML
AD  - Endocrinology Section, Biotherapeutics, National Institute for Biological 
      Standards and Control (NIBSC), Blanche Lane, Potters Bar EN6 3QG, UK.
LA  - eng
PT  - Journal Article
DEP - 20200113
PL  - United States
TA  - Mol Ther Methods Clin Dev
JT  - Molecular therapy. Methods & clinical development
JID - 101624857
PMC - PMC7005462
EDAT- 2020/02/15 06:00
MHDA- 2020/02/15 06:01
PMCR- 2020/01/13
CRDT- 2020/02/15 06:00
PHST- 2019/10/02 00:00 [received]
PHST- 2019/12/28 00:00 [accepted]
PHST- 2020/02/15 06:00 [entrez]
PHST- 2020/02/15 06:00 [pubmed]
PHST- 2020/02/15 06:01 [medline]
PHST- 2020/01/13 00:00 [pmc-release]
AID - S2329-0501(20)30006-1 [pii]
AID - 10.1016/j.omtm.2019.12.015 [doi]
PST - epublish
SO  - Mol Ther Methods Clin Dev. 2020 Jan 13;16:161-171. doi: 
      10.1016/j.omtm.2019.12.015. eCollection 2020 Mar 13.